Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7660175 | 0.88 | ALDH1A1 (0.54) | ALDH1A1EGFRRAB9AHDAC3HDAC4 | |
| SCHEMBL5369204 | 0.85 | ALDH1A1 (0.65) | ALDH1A1RAB9AHTTNPSR1LMNA | |
| SCHEMBL5369201 | 0.85 | ALDH1A1 (0.65) | ALDH1A1RAB9AHTTNPSR1LMNA | |
| SCHEMBL8009713 | 0.83 | KMT2A (0.63) | ALDH1A1EGFRRAB9AHDAC3HDAC4 | |
| SCHEMBL8007826 | 0.83 | KMT2A (0.63) | ALDH1A1EGFRRAB9AHDAC3HDAC4 | |
| SCHEMBL7663088 | 0.82 | RAB9A (0.63) | ALDH1A1EGFRRAB9AHDAC3HDAC4 | |
| SCHEMBL7661431 | 0.82 | ALDH1A1 (0.69) | ALDH1A1EGFRRAB9AHDAC3HDAC4 | |
| SCHEMBL3105207 | 0.80 | HAO1 (0.62) | ALDH1A1EGFRRAB9ANPSR1LMNA | |
| SCHEMBL3105202 | 0.80 | HAO1 (0.62) | ALDH1A1EGFRRAB9ANPSR1LMNA | |
| SCHEMBL6971897 | 0.80 | TDP1 (0.65) | ALDH1A1EGFRRAB9AHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344462-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-6127389-A | TREATMENT OF HYPERTENSION, RENAL DISEASES, HEART FAILURE, HYPERTENSION, MENIERE'S DISEASE, PERIPHERAL AND CEREBRAL CIRCULATORY DISORDERS, CLIMACTERIC DISTURBANCE, RETINOCHOROIDAL CIRCULATORY DISORDERS, MYOCARDIAL ISCHEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6083959-A | BRADYKININ ANTAGONISTS; FOR THE PREVENTION AND/OR THE TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-6015818-A | TREATING KIDNEY, BRAIN, AND CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1997041104-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997028153-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-07 | — | — | WO | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |